



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of

Sylvain FLEURY et al.

Application No.: 10/573,704

Filed: March 27, 2006

Docket No.: 122481

For: NEW SOLUBLE AND STABILIZED TRIMERIC FORM OF GP41 POLYPEPTIDES

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- ☒ 2. Relevance of one or more non-English language reference is discussed in the present specification. See References 1 and 10.
- ☒ 3. One or more reference cited herein was cited in a counterpart foreign application. An English language version of the foreign search report is attached for the Examiner's information. See References 2-9.
- ☒ 4. In accordance with 37 CFR §1.98(a)(2)(ii), copies of any U.S. patents and patent application publications are not attached.
- ☒ 5. Reference 1 corresponds to reference 3.

Respectfully submitted,


  
James A. Oliff  
Registration No. 27,075

Stephen P. Catlin  
Registration No. 36,101

JAO:SPC/aha

Date: October 20, 2006  
OLIFF & BERRIDGE, PLC  
P.O. Box 19928  
Alexandria, Virginia 22320  
Telephone: (703) 836-6400

DEPOSIT ACCOUNT USE AUTHORIZATION Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461
--

Sheet 1 of 1

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 122481		APPLICATION NO. 10/573,704	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)				APPLICANT(S) Sylvain FLEURY et al.			
				FILING DATE March 27, 2006			
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Name			
	1	6,455,265 B1	09/24/2002	Serres			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation	
	2	WO 02/34909 A2	05/02/2002	WIPO			
	3	WO 99/25377 A1	05/27/1999	WIPO			
OTHER DOCUMENTS							
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)					
	4	Louis J M, et al; (2001); "Design and Properties of Nccg-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity"; Journal of Biological Chemistry; vol. (276); pp. 29485-29489.					
	5	Eckert D M, et al; (2001); "Design of Potent Inhibitors of HIV-1 Entry From the gp41 N-peptide Region"; Proceedings of the National Academy of Science of USA; vol. (98); pp. 11187-11192.					
	6	Root M J, et al; (2001); "Protein Design of an HIV-1 Entry Inhibitor"; Science; vol. (291); pp. 884-888.					
	7	Lu M, et al; (1999); "Subdomain Folding and Biological Activity of the Core Structure from Human Immunodeficiency Virus Type 1 gp41: Implications for Viral Membrane Fusion"; Journal of Virology; vol. (73); pp.4433-4438.					
	8	Serres P F, "Molecular Mimicry Between the Trimeric Ectodomain of the Transmembrane Protein of Immunosuppressive Lentiviruses (HIV-SIV-FIV) and Interleukin 2"; Life Sciences; vol. (323); pp. 1019-1029.					
	9	Serres P F; (2001); "AIDS: an Immune Response Against the Immune System. Role of a Precise Tridimensional Molecular Mimicry"; Journal of Autoimmunity; vol. (16); pp. 287-291.					
	10	Cavaillon J M, (1966); "Le Monde Des Cytokines"; pp. 1-12.					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: October 20, 2006